

PCTWORLD INTELLECTU
Inter

INTERNATIONAL APPLICATION PUBLISHED

WO 9603973A1

(51) International Patent Classification⁶:

A61K 7/48, 9/00, 7/16

A1

(11) International Publication Number:

WO 96/03973

(43) International Publication Date:

15 February 1996 (15.02.96)

(21) International Application Number: PCT/EP95/02999

(22) International Filing Date: 28 July 1995 (28.07.95)

(30) Priority Data:

MI94A001668

1 August 1994 (01.08.94)

IT

(71) Applicant (for all designated States except US): LIFEGROUP S.P.A. [IT/IT]; Viale Tre Venezie, 44-46, I-35043 Monselice (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DELLA VALLE, Francesco [IT/IT]; Via Cerato, 14, I-35122 Padova (IT). LORENZI, Silvana [IT/IT]; Piazza Napoli, 17, I-35142 Padova (IT). CERINI, Roberto [IT/IT]; Via Ronchi, 4, I-35127 Padova (IT). MARCOLONGO, Gabriele [IT/IT]; Strade Interne 5 Terra, I-35020 Carrara S. Giorgio (IT).

(74) Agent: PASSINI, Angelo; Notarbartolo & Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milan (IT).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: HIGHLY BIOADHESIVE AND MUCOADHESIVE COMPOSITIONS FOR THE TREATMENT OF EPITHELIA AND MUCOUS MEMBRANES

(57) Abstract

Compositions having high bioadhesion, mucoadhesion and viscoelasticity, containing mixtures of synthetic polymers, such as polyvinyl alcohol and Polycarbophil, and of biopolymers, such as alginic acid, hyaluronic acid and dermatan sulfate, useful in the treatment of skin and mucosal tissues dryness and dehydration, and suitable as vehicles for active ingredients in percutaneous absorption.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HIGHLY BIOADHESIVE AND MUCOADHESIVE COMPOSITIONS FOR THE TREATMENT OF
EPITHELIA AND MUCOUS MEMBRANES

FIELD OF THE INVENTION

The present invention relates to aqueous compositions containing mixtures of synthetic polymers and biopolymers, useful in the treatment of skin and mucosal tissues dryness, and suitable as vehicles of active ingredients.

PRIOR ART DISCLOSURE

- 5 Skin and mucosal tissues dryness and dehydration are very frequent conditions and may be caused by environmental factors, viruses, bacteria, or associated with etiologically different primary diseases. When affecting mucous membranes, said conditions are usually described as dryness of the buccal cavity (e.g. dry stomatopharyngitis in Sjögren's
10 syndrome), of the vaginal, nasal and intestinal mucous membranes, and dryness of the eye (e.g. keratitis sicca).

Skin dryness and/or dehydration are not only important from an aesthetic point of view, but above all said conditions represent alterations of the cutis physiological function as a protective and defensive barrier.

- 15 Furthermore, said dryness, which is per se a tissual damage causing lesions in the most serious cases, is also a hindrance to the absorption of possible products and/or drugs that can be administered in the treatment of the diseases affecting said tissues.

- The methods most commonly used in the restoration of adequate moisture
20 levels and in the prevention of further dehydration of the tissues consist in the application of creams, lotions or gels, which are capable of supplementing the water content of the tissues with highly hydrophilic

- 2 -

agents or capable of forming a hydrophobic impermeable barrier on the tissue to be treated.

In the former case, it is well known in the state of the art the use of small synthetic hydrophilic molecules having humectant properties, such as glycerol, optionally mixed with water; it is also well known the use of macromolecules physiologically present in the tissues such as mucopolysaccharides, i.e. hyaluronic acid, dermatan sulfate and chondroitin sulfate, proteins such as collagen, elastin and placental proteins, having good properties as moisturizers and humectants.

As regards percutaneous absorption of active principles, it is to be stressed that the biological response to an active ingredient is often influenced by factors unrelated to the administered amount of the same principle. In particular, this is typical of topical administrations designed for local effect "in situ" as well as of oral administrations designed for absorption by general routes, which is often incomplete or in any case variable. In fact it is known that the bioavailability of active principles may be limited by the residence and contact times with the surface where absorption has to occur, e.g. the gastrointestinal tract in the case of oral preparations.

Therefore, several research works have lately been oriented to the development of bio- and/or mucoadhesive matrixes capable of binding themselves both to the stratum corneum of the cutis and to the film covering the mucous membranes, in particular the nasal one of the upper respiratory tract, the buccal, rectal, vaginal and ophthalmic ones.

The term "bioadhesion" has traditionally been used to describe the aggregation of biological and non-biological materials, rather than the interaction between materials having both biological origin. When the

- 3 -

mucous membrane is covered by mucus, it is necessary to introduce the concept of mucoadhesion, which means that it is the same layer of mucus that comes into close contact with the adhesive substance through a typical "interface" phenomenon involving the interpenetration of the two phases.

Therefore, the "efficiency" of a bioadhesive matrix is influenced by specific physical and thermodynamic parameters, which determine the adhesion strength, and in particular by:

- i) the "adhesive" molecular weight (e.g. the polyethylene glycol adhesiveness seems to increase with increasing the molecular weight, up to an optimal value of 4,000,000);
- ii) the molecular mobility, which favours diffusion, and a sufficiently high viscosity;
- iii) the ability to swell and form gels by osmosis with the substrate;
- iv) the presence of functional groups capable of forming hydrogen bonds, such as carboxyl, hydroxyl, amido and sulphate groups.

However, the single parameters, though often related to the bioadhesive properties, are a necessary but not a sufficient condition for an adequate bioadhesive behaviour.

Among the substances having physicochemical properties predisposing to good bioadhesion and/or mucoadhesion, there are the aforesaid polysaccharides of biological derivation from mammalian tissues (hyaluronic acid, dermatan sulfate and chondroitin sulfate) as well as the polysaccharides of vegetable derivation, mostly from algae, such as alginic acid, gellan and other related mucopolysaccharides.

Other polysaccharides are cellulose and derivatives thereof (alkyl and carboxyalkyl), chitosan and chitin.

- 4 -

In addition to such polymers, synthetic polymers belonging to the families of polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol and Carbopol are also to be mentioned. An exemplary highly hydrophilic and highly bioadhesive polymer is Carbopol Ex-55[®], denominated
5 Polycarbophil.

The bioadhesive behaviour of some compounds may be studied by in vitro, in vivo and ex vivo specific methods allowing qualitative and quantitative determinations (H.E. Junginger, *Pharm. Ind.*, 53, 11, 1056-1065, 1991).

10 Measurements made by said methods showed that Polycarbophil, the polymer mentioned above, has excellent adhesion strength and mucoadhesive properties, which were evaluated to be higher than 200% referred to the properties of pectin, which reference value was assumed 100%; sodium alginate was found to have satisfactory adhesion strength and
15 mucoadhesive properties, evaluated at 126% approx.; instead, the mucoadhesion strength of polyvinyl alcohol was found to be 94.8% (H.E. Junginger, *ibid.* 1991).

The studies made in order to evaluate the ability of mucoadhesive polymers to act as vehicles of drugs and to release same at a controlled
20 rate showed that some solutions containing Carbopol 934[®] slow the ileocecal transit (D. Harris et al., *J. of Controlled Release*, 12, 55-56, 1990), while Polycarbophil increases the intestinal absorption of peptidergic drugs (C.M. Lehr et al., *J. Pharm. Pharmacol.*, 44, 402-407, 1992), polyvinyl alcohol increases the topical bioavailability of
25 miconazole (M.F. Saettone et al., *J. of Controlled Release*, 16, 197-202, 1991) and sodium hyaluronate significantly increases the bioavailability of pilocarpine (M.F. Saettone, *Int. J. of Pharmaceutics*, 72, 131-139,

1991).

SUMMARY OF THE INVENTION

The Applicant has found aqueous compositions containing mixtures of synthetic polymers and biopolymers at different per cent ratios; said mixtures unexpectedly exhibit higher bioadhesive properties than those of the polymers that are now recognized to have said properties to an optimal degree, such as Polycarbophil.

Said mixtures essentially consist of synthetic polymers, such as Polycarbophil and polyvinyl alcohol, associated with biopolymers, such as hyaluronic acid, alginic acid or dermatan sulfate, in the acidic form or in the form of salts thereof, in varying proportions.

The viscous behaviour of said compositions is characterized by particular physicochemical properties that substantially differentiate same from aqueous compositions containing only bioadhesive synthetic polymers; it follows that the topical application of the compositions of the invention is particularly advantageous. Said advantages arise from the bioadhesive and, in particular, the viscoelastic characteristics, as well as from the film-forming properties of said compositions.

It is a further object of the present invention the use of said compositions in the rehydration of skin or mucous membranes and/or as vehicles of active principles by topical application on said tissues.

It is a further object of the present invention to provide new compounds, i.e. dermatan sulfate and hyaluronic acid zinc salts, dermatan sulfate tetrabutylammonium salt, and mixed salts of dermatan sulfate or of hyaluronic acid with biotin and ethylenediamine, or with traumatic acid and ethylenediamine.

- 6 -

BRIEF DESCRIPTION OF THE DRAWINGS

The rheological properties and viscoelastic behaviour of the compositions according to the present invention will be better understood by reference to the enclosed drawings, wherein:

Figures 1a to 7a illustrate the flow curves (rheograms) relating respectively to samples B, A, D, H, I, C and G;

Figures 1b to 7b illustrate the oscillatory measurements relating respectively to samples B, A, D, H, I, C and G.

DETAILED DESCRIPTION OF THE INVENTION

The characteristics and advantages of the compositions according to the present invention will be better illustrated in the following detailed description.

The synthetic polymers used in the compositions of the present invention are selected from the group consisting of polyethylene glycols, polyvinylpyrrolidone, polyvinyl alcohol and derivatives thereof, Carbopol and derivatives thereof; and preferably said synthetic polymers are polyvinyl alcohol or Polycarbophil.

Polyvinyl alcohol is a polymer having formula $(-\text{CH}_2-\text{CHOH}-)_n$, prepared by alcoholysis of polyvinyl acetate.

The polymer found in commerce is characterized by different degrees of acetylation, which determine different physicochemical properties. Depending on the degree of polymerization, it may be soluble in aqueous solutions giving colloidal solutions, or in mixtures of water and alcohol.

This polymer is widely used in the industry of plastics and textiles as a non-ionic surfactant. In the pharmaceutical industry, it is employed in the ophthalmic field to prepare useful solutions per se, e.g. artificial

- 7 -

t ars, or as a vehicle of ophthalmic drugs. It is also used in dermatology and for the cosmetic treatment of the skin (Martindale, *Extra Pharmacopeia*, 29th Ed., Pharmaceutical Press, 1989).

The other preferred synthetic polymer is Polycarbophil, a polyacrylic acid cross-linked with divinyl glycol (3,4-dihydroxy-1,5-hexadiene). The main characteristic of this polymer is a high water absorbing power; due to said physicochemical property, it is used in the form of calcium salt as a cathartic (Martindale, *Extra Pharmacopeia*, 29th Ed., Pharmaceutical Press, 1989). The use of said polymer as moisturizer and humectant is disclosed in European patent application No. 0 429 156 A1 and as a bioadhesive vehicle for the controlled release of active principles, in the pharmaceutical field, in US patent No. 4,615,697.

The biopolymers used can be obtained from mammalian tissues, such as hyaluronic acid, dermatan sulfate and chondroitin sulfate, which play a key role in differentiation, growth and migration of cells, as well as in extracellular matrix organization; or they can be obtained from vegetables, such as alginic acid. Said polysaccharides are characterized by specific and distinctive functional groups, but they all show a high molecular weight and a marked hydrophilic power.

In particular, alginic acid, a polyuronic acid extracted from algae and composed of mannuronic and L-guluronic acid residues, is amply used in the food industry as thickener and in the pharmaceutical industry as antiacid and, in the form of calcium salt, as haemostatic. Hyaluronic acid and dermatan sulfate, deriving on the opposite from animal tissues, are characterized the form r by glucuronic acid and glucosamine, and th latter by iduronic acid and sulphate groups.

Among the above m ntioned biopolymers, hyaluronic acid has been

- 8 -

particularly studied concerning both its biological role and th
pharmacological or cosmetic properties. Recent studies have shown that
hyaluronic acid is the most specific ligand of CD44 receptor, a protein
localized on cell surface. It is to be noted that CD44 is also abl to
5 bind, with a lower affinity, chondroitin-4-sulfate and chondroitin-6-
sulfate (Aruffo et al. "CD44 is the principal cell surface receptor for
-hyaluronate", *Cell*, 61: 1303-1313, 1990). To further specify such a
functional interaction, it has been shown that CD44 receptor and
hyaluronic acid are co-distributed in epithelia having similar functi nal
10 program, i.e. keratinizing oral epithelium, hair follicle and nail cells
(C. Wang et al. "Distribution of hylauronan and its CD44 receptor in the
epithelia of human skin appendages", *Histochemistry*, 98: 105-112, 1992).
According to these evidences, hyaluronic acid has found extensive
pharmaceutical applications in the osteoarticular, ophthalmic and
15 dermatologic fields and for the cosmetic treatment of the skin. Also its
homologue chondroitin sulfate is widely used in the pharmaceutical field
as an anti-hyperlipoproteinaemic agent in atherosclerosis and as
artificial tears in the form of eyewash.

High molecular weight dermatan sulfate is used because of its
20 anticoagulant properties, analogous to those of heparin. However, said
properties are not observed in the low molecular weight polymer (F. Dol
et al., *J. Lab. Clin. Med.*, 115, 1, 43-51, 1990).

Moreover, it is noteworthy the fact that the presence in the bioadhesive
and mucoadhesive compositions of the invention of biopolymers able to
25 bind, through a well defined epitope, to a specific receptor, such as
hyaluronan and CD44, leads to a pr fer ntial distribution via receptor-
binding of the biopolymers th mselves, as w ll as th active principl s

- 9 -

optionally delivered.

All the above biopolymers are usually used in the form of sodium salt; however, in the preparation of the aforesaid bioadhesive compositions, they can be used also in the form of other commonly available salts, such as salts of alkali or alkaline-earth metals and ammoniac salts.

Furthermore, said biopolymers can be used in the form of new salts, such as lithium and zinc salts, or mixed salts with a diamino compound, such as ethylenediamine or piperazine, and a biocompatible compound having a carboxylic group, such as biotin or traumatic acid, which form a further object of the present invention. More specifically, salification is carried out by bridging the carboxylic groups of the biopolymer and of said biocompatible compound by means of a suitable organic compound carrying at least two amino groups, such as for example ethylenediamine or piperazine, or carrying at least two quaternary ammoniac substituents.

Said mixed salts of biopolymers, according to the present invention, are preferably the salt with biotin and ethylenediamine, and the salt with traumatic acid and ethylenediamine, particularly suitable for supplying oligoelements or vitamins to the tissue (skin or mucous membranes) treated with the compositions of the invention.

The methods for the preparation of the above mentioned salts may vary depending on the polysaccharide nature and physico-chemical characteristics. In fact, some polysaccharides are water-soluble both in the acidic and salified forms (Methods 1 and 2), while some others are poorly water-soluble in the acidic form and soluble in the form of salts (Methods 3 and 4). Finally, other polysaccharides are soluble in the acidic form and water-insoluble in the form of salts (Methods 5 and 6).

We report hereinafter suitable methods of preparation of the aforesaid

- 10 -

salts, corresponding to the above cases; some of them are already known in the state of the art, while others, even if new, are easily deducible by the men skilled in the art.

Said methods allow the obtainment of salts of mono and bivalent ions, as well as of higher-valence ions, which can salify the carboxylic groups of the polysaccharide; moreover, according to the reported preparation procedures, it is possible to obtain salts of the aforesaid biopolymers with primary, secondary or tertiary organic amines, or with quaternary ammonic compounds.

Furthermore, said methods may be conveniently used to obtain the mixed salts of said biopolymers with diaminic compounds and biocompatible compounds having a carboxylic group.

Method I

A quantity of salified polysaccharide in the most currently available form, generally the sodium salt, partially salified to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is eluted in a column cooled to 4°C, containing a slight excess of a cationic exchange resin such as 50x8 Dowex[®], generated in H⁺ form. The sodium-free eluate is collected under continued stirring in a solution cooled to 4°C and containing an equivalent amount of the counterion with which the polysaccharide is to be salified, properly prepared in the free base form. The obtained product may be collected by precipitation in a non-solvent or by drying processes operating under mild conditions, such as lyophilization or spray-drying.

Method II

A quantity of salified polysaccharide in the most currently available

- 11 -

form, generally the sodium salt, partially salified to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is dialyzed at 4°C vs. an aqueous solution of a salt (MX) of the cation with which the polymer is to be salified until the dialyzate is sodium-free and then vs. distilled water to remove excess MX, if any. The obtained product may be collected by precipitation in a non-solvent or by drying processes operating under mild conditions, such as lyophilization or spray-drying.

Method III

A quantity of salified polysaccharide in the most currently available form, generally the sodium salt, partially salified to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is eluted in a column cooled to 4°C, containing a slight excess of a cationic exchange resin such as 50x8 Dowex[®], generated in the ionic form of the counterion with which polymer is to be salified. The product contained in the eluate may be collected by precipitation in a non-solvent or by drying processes operating under mild conditions, such as lyophilization or spray-drying.

Method IV

A quantity of salified polysaccharide in the most currently available form, generally the sodium salt, partially salified to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is slowly added with an equivalent amount of mineral acid, under continued stirring, at 4°C. The polysaccharide that precipitates in the acidic form is separated by filtration, washed and suspended again in distilled water at 4°C. An equivalent amount of the counterion with which the polymer is

- 12 -

to be salified, properly prepared in the free base form is added to the polymer suspension in the acidic form. The soluble salt obtained by salification may be collected by precipitation in a non-solvent or by drying processes operating under mild conditions, such as lyophilization or spray-drying.

Method V

A quantity of polysaccharide partially salified with an alkaline earth metal (Ca^{++} or Ba^{++}) to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is added slowly and under continued stirring with an equivalent amount of a suitable salt of the counterion with which the polymer is to be salified, properly salified with an anion bringing about the formation of a precipitate with the alkaline earth metal; the formation of insoluble calcium or barium sulphate will be particularly convenient. The precipitate is separated by filtration and discarded, while the product contained in the solution may be collected by precipitation in a non-solvent or by drying processes operating under mild conditions, such as lyophilization or spray-drying.

Method VI

A quantity of salified polysaccharide in the most currently available soluble form, generally the sodium salt, partially salified to obtain 1.0 equivalent of free anionic functional groups (carboxyls and/or sulphates), is solubilized in distilled water. The solution is added slowly and under continued stirring with an equivalent solution of a convenient salt of the cation with which the polymer is to be salified, preferably a halide, sulphate, nitrate or acetate of said cation. The precipitate is separated by filtration, washed and dried under vacuum.

- 13 -

while the solution is discarded.

We report hereinbelow for illustrative but not limitative purposes the following examples describing the preparation of the new hyaluronic acid and dermatan sulfate salts of the present invention, according to the general methods described above.

EXAMPLE 1

Preparation of dermatan sulfate lithium salt

Dermatan sulfate sodium salt (25.2 g), having an average molecular weight of 5,000 to 8,000 daltons, was solubilized in distilled water (200 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex® (120 ml), generated in Li⁺ form. The sodium-free eluate was frozen and lyophilized to give 23.3 g of product. The physicochemical properties of the dermatan sulfate lithium salt are as follows:

physical state	whitish amorphous powder
empirical formula	C ₁₄ H ₁₉ NO ₁₄ SLi ₂
molecular weight	471.26 (disaccharide unit)
elemental analysis theoretical:	C=35.68%; H=4.06%; N=2.97%; O=47.53%; S=6.80%; Li=2.95%
experimental:	C=35.55%; H=4.10%; N=2.92%; O=47.70%; S=6.68%; Li=2.90%
water solubility	>10 mg/ml

EXAMPLE 2

Preparation of dermatan sulfate zinc salt

Dermatan sulfate sodium salt (25.2 g), having an average molecular weight

- 14 -

of 5,000 to 8,000 daltons, was solubilized in distilled water (200 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (120 ml), generated in Zn⁺⁺ form. The sodium-free eluate was frozen and lyophilized to give 26.05 g of product.

5 The physicochemical properties of the dermatan sulfate zinc salt are as follows:

physical state	whitish amorphous powder
empirical formula	C ₁₄ H ₁₉ NO ₁₄ SZn
molecular weight	522.74 (disaccharide unit)
10 elemental analysis theoretical:	C=32.17%; H=3.66%; N=2.68%; O=42.85%; S=6.13%; Zn=12.51%
	experimental: C=32.05%; H=3.72%; N=2.63%; O=42.92%; S=6.15%; 15 Zn=12.48%
water solubility	>10 mg/ml

EXAMPLE 3

Preparation of hyaluronic acid zinc salt

Hyaluronic acid sodium salt (40.1 g), having an average molecular weight of 1,000,000 daltons, was solubilized in distilled water (8,000 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (120 ml), generated in Zn⁺⁺ form. The sodium-free eluate was frozen and lyophilized to give 40.8 g of product.

20 The physicochemical properties of the hyaluronic acid zinc salt are as follows:

physical state	whitish amorphous powder
25 empirical formula	C ₁₄ H ₂₀ NO ₁₁ Zn _{1/2}

- 15 -

molecular weight 411.0 (disaccharide unit)
elemental analysis theoretical: C=40.91%; H=4.90%; N=3.41%;
O=42.82%; Zn=7.95%
experimental: C=40.80%; H=4.97%; N=3.38%;
O=43.00%; Zn=7.81%
water solubility >5 mg/ml

EXAMPLE 4**Preparation of dermatan sulfate mixed salt with biotin and ethylenediamine**

Dermatan sulfate sodium salt (50.3 g), having an average molecular weight of 5,000 to 8,000 daltons, was solubilized in distilled water (500 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex® (240 ml), generated in H⁺ form. The sodium-free eluate was collected under continued stirring in a solution cooled to 4°C, containing biotin (48.8 g) and ethylenediamine (12.0 g). The resulting solution was frozen and lyophilized to give 106.2 g of product.

The physicochemical properties of the low molecular weight dermatan sulfate mixed salt with biotin and ethylenediamine are as follows:

physical state whitish amorphous powder
empirical formula $C_{38}H_{69}N_9O_{20}S_3$
molecular weight 1068.19 (disaccharide unit)
elemental analysis theoretical: C=42.73%; H=6.51%; N=11.80%;
O=29.96%; S=9.00%
experimental: C=42.65%; H=6.60%; N=11.64%;
O=29.74%; S=6.25%
biotin - 45.74% (w/w)

- 16 -

water solubility >10 mg/ml

EXAMPLE 5

Preparation of dermatan sulfate mixed salt with traumatic acid and ethylenediamine

Dermatan sulfate sodium salt (50.3 g), having an average molecular weight of 5,000 to 8,000 daltons, was solubilized in distilled water (500 ml).

The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (240 ml), generated in H⁺ form. The sodium-free eluate was collected under continued stirring in a solution cooled to 4°C, containing traumatic acid (22.8 g) and ethylenediamine (12.0 g). The resulting solution was frozen and lyophilized to give 80.3 g of product.

The physicochemical properties of the low molecular weight dermatan sulfate mixed salt with traumatic acid and ethylenediamine are as follows:

physical state	whitish amorphous powder
empirical formula	$C_{30}H_{57}N_5O_{18}S$
15 molecular weight	807.86 (disaccharide unit)
elemental analysis	theoretical: C=44.60%; H=7.11%; N=8.67%;
	O=35.65%; S=3.97%
	experimental: C=44.65%; H=7.18%; N=8.54%;
	O=35.72%; S=3.91
20 traumatic acid	28.26% (w/w)
water solubility	>10 mg/ml

EXAMPLE 6

Preparation of hyaluronic acid mixed salt with biotin and ethylenediamine

Hyaluronic acid sodium salt (40.1 g), having an average molecular weight

- 17 -

of 1,000,000 daltons, was solubilized in distilled water (8,000 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (120 ml), generated in H⁺ form. The sodium-free eluate was collected under continued stirring in a solution cooled to 4°C, containing biotin (24.4 g) and ethylenediamine (6.0 g). The resulting solution was frozen and lyophilized to give 67.9 g of product. The physicochemical properties of the high molecular weight hyaluronic acid mixed salt with biotin and ethylenediamine are as follows:

physical state	whitish amorphous powder
10 empirical formula	C ₂₆ H ₄₅ N ₅ O ₁₄ S
molecular weight	683.73 (disaccharide unit)
elemental analysis theoretical:	C=45.67%; H=6.63%; N=10.24%; O=32.67%; S=4.69%
	experimental: C=45.24%; H=6.85%; N=10.18%; 15 O=33.12%; S=4.61%
biotin	35.73% (w/w)
water solubility	>10 mg/ml

EXAMPLE 7

Preparation of hyaluronic acid mixed salt with traumatic acid and ethylenediamine

Hyaluronic acid sodium salt (40.1 g), having an average molecular weight of 1,000,000 daltons, was solubilized in distilled water (8,000 ml). The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (120 ml), generated in H⁺ form. The sodium-free eluate was collected under continued stirring in a solution cooled to 4°C, containing traumatic acid (11.4 g) and ethylenediamine (6.0 g). The resulting solution was frozen and lyophilized to give 67.9 g of

- 18 -

product.

The physicochemical properties of the high molecular weight hyaluronic acid mixed salt with traumatic acid and ethylenediamine are as follows:

	physical state	whitish amorphous powder
5	empirical formula	$C_{22}H_{39}N_3O_{13}$
	molecular weight	553.56 (disaccharide unit)
	elemental analysis theoretical:	C=47.74%; H=7.10%; N=7.59%; O=37.57%
		experimental: C=47.34%; H=7.18%; N=7.46%; O=38.02%
10	traumatic acid	20.62% (w/w)
	water solubility	>10 mg/ml

EXAMPLE 8

Preparation of dermatan sulfate tetrabutylammonium salt

Dermatan sulfate sodium salt (25.2 g), having an average molecular weight of 5,000 to 8,000 daltons, was solubilized in distilled water (200 ml).

- 15 The solution was eluted in a column cooled to 4°C, containing the cationic exchange resin 50x8 Dowex[®] (120 ml), generated in the tetrabutylammonium form. The sodium-free eluate was frozen and lyophilized to give 47.0 g of product.

The physicochemical properties of the dermatan sulfate tetrabutylammonium

- 20 salt are as follows:

	physical state	whitish amorphous powder
	empirical formula	$C_{46}H_{93}N_3O_{14}S$
	molecular weight	944.33 (disaccharide unit)
	elemental analysis theoretical:	C=58.51%; H=9.93%; N=4.45%; O=23.72%; S=3.40%

25

- 19 -

experimental: C=58.23%; H=10.01%; N=4.51%;

O=23.78%; S=3.47%

water solubility >10 mg/ml

The bioadhesive and mucoadhesive compositions according to the present invention contain synthetic and biological polymers preferably at the following concentrations: polyvinyl alcohol, at a concentration ranging from 0.1 to 4% by wt., Polycarbophil at a concentration ranging from 0.1 to 2% by wt., hyaluronic acid having an average molecular weight of 800,000 to 1,200,000 daltons or salts thereof at a concentration ranging from 0.05% to 5% by wt., low and medium viscosity alginic acid or salts thereof at a concentration ranging from 0.5% to 5% by wt., dermatan sulfate having average molecular weight of 5,000 to 8,000 daltons and salts thereof at a concentration ranging from 0.05% to 5% by wt.

The bioadhesive and viscoelastic aqueous compositions of the invention may consist of binary, ternary or quaternary associations of said synthetic and biological polymers, depending on the requirements as well as on the desired degree of bioadhesion and/or physicochemical and rheological properties.

Due to their physicochemical properties, such bioadhesive compositions adhere to mammalian skin and mucous membranes, moisturizing and protecting same from irritative agents. Furthermore, they may usefully be employed in the administration of active principles: in fact, compared with non-bioadhesive matrixes, they improve bioavailability of active principles by prolonging the contact time with the skin or mucosa. In fact, bio- and mucoadhesive bases are active "in loco" for approx. 10-20 hours, i. . for the period equivalent to the time of turnover of the strata cornea of the epidermis or of mucin. Therefore, a prolonged

- 20 -

contact time results in an improved absorption of the active principle.

Furthermore, compared with the compositions known in the state of the art, the claimed compositions, which contain both biopolymers and synthetic polymers, offer the advantage of a higher biocompatibility with the contacted tissues, when applied to the site where they have to exert their action.

Therefore, the bioadhesive compositions according to the present invention are suitable for the prevention and treatment of conditions characterized by excessive skin and mucous membranes dryness (of the mouth, nose, upper respiratory tract, gastrointestinal tract, eye and vagina), even when induced by irritants and physiopathologic causes. Furthermore, being primarily capable of correcting the skin and mucous membranes alterations caused by dehydration, the bioadhesive compositions of the invention also act as vehicles of active principles, whereby the active principles bioavailability is improved, the residence time "in situ" prolonged and/or the absorption improved.

The bioadhesive compositions according to the present invention are prepared by a method consisting of sequential steps. It is described herein by way of example, for illustrative but not limitative purposes, the preparation of a composition containing two synthetic polymers (Polycarbophil and polyvinyl alcohol), a biopolymer (hyaluronic acid) and triethanolamine as salifying agent of the polymers and as thickener.

EXAMPLE 9

Preparation of the compositions of the invention

1) A planetary turboemulsifier of stainless steel provided with paddles counterrotating at variable speed and with heating/cooling jacket was fed, under constant agitation, in the order with demineralized water (50%

- 21 -

by wt. of the total) and Polycarbophil. The turboemulsifier was work d under vacuum at -76 mmHg. for at least 15 min.

Once turboemulsifying had been completed, the mass was maintained under stirring at high shear rates until perfect homogenization.

- 5 2) At the same time, a melter of stainless steel, equipped with heating jacket and counterrotating paddles, was fed in the order with demineralized water (35.55% by wt. of the total) and polyvinyl alcohol. The melter was heated to $85 \pm 2^{\circ}\text{C}$. At that temperature, the mass was maintained under mixing until a perfectly clear solution was obtained.
- 10 3) Once the two aforesaid steps had been completed, the mass contained in the melter was added slowly, under continuous stirring and in a thin stream, to the mass contained in the planetary turboemulsifier, whose inside was maintained under constant vacuum. The resulting mass was maintained under continuous stirring until a completely homogeneous phase
- 15 was obtained. The resulting mass was cooled under vacuum to $30 \pm 2^{\circ}\text{C}$. At that temperature, the mass was maintained under stirring and in vacuo.
- 4) Solution A was separately prepared in a suitable vessel of stainless steel, provided with agitator, by addition in the order of demineralized water (10% by wt. of the total) and of a biopolymer, e.g. hyaluronic
- 20 acid. Agitation was continued until a viscous, perfectly homogeneous and clear solution was obtained.
- 5) Solution A was added slowly and in a thin stream to the mass contained in the turboemulsifier, under continuous stirring and under constant vacuum at -76 mmHg. Agitation was continued until a perfectly homogeneous
- 25 mass was obtained.

A gel of th desired density may be obtain d by adding for exampl triethanolamine and operating according to the following steps.

- 22 -

subsequent to step 5):

6) Solution B consisting of demineralized water (1% by wt. of the total) and triethanolamine was prepared instantly in a suitable vessel of stainless steel.

- 5 7) Solution B was added under continuous stirring to the mass contained in the turboemulsifier. Agitation was continued until complete carbomers swelling and a perfectly homogeneous gel were obtained. Once the mass had gelled completely, mixing was stopped and the pressure inside the turboemulsifier was slowly restored. The gelled mass was then discharged
10 into containers of stainless steel.

For illustrative but not limitative purposes, the physicochemical properties of the compositions according to the present invention, obtained by the aforesaid method, are herein reported in Table 1. Concentrations are by weight; balance to 100 is water.

Table 1 Physicochemical properties of bioadhesive formulations

Bioadhesive comp.	Conc. %	pH	Viscosity	Density	Ref.
Polycarbophil	1.00	5.2±0.5	3.100	1.0050	C
Polyvinyl alcohol	1.50				
Hyaluronic acid	0.15				
Polycarbophil	0.20	5.3±0.5	230	1.0020	D
Polyvinyl alcohol	0.30				
Hyaluronic acid	0.15				
Polycarbophil	1.00	6.8±0.5	2,700	1.0100	E
Polyvinyl alcohol	1.50				
Sodium Alginate	1.00				
Polycarbophil	1.00	6.5±0.5	6,000	1.0200	F
Polyvinyl alcohol	1.50				
Sodium Alginate	2.00				
Polycarbophil	1.00	6.6±0.5	10,000	1.0250	G
Polyvinyl alcohol	1.50				
Sodium Alginate	3.00				
Polycarbophil	0.20	5.2±0.5	400	1.0050	H
Polyvinyl alcohol	1.50				
Hyaluronic acid	0.30				
Polycarbophil	0.20	5.2±0.5	50	1.0050	I
Polyvinyl alcohol	1.50				
Dermatan sulfate	0.15				

- Viscosity, expressed as centipoises (cp) at 20°C, was measured with a viscometer CONTRAVES[®] TVB.

- Density (relative 20/20°C) was measured with a picnometer for

- 24 -

semifluids vs. the density of water.

Measurement of bioadhesive properties

In order to check the bioadhesive properties, the adhesion strength of the aforesaid compositions (marked C to I) was evaluated in comparison with mucin, Carbopol 940® and the bioadhesive polymer Polycarbophil at a concentration of 1% by wt. (composition A) and of 0.20% by wt. (composition B) in water, i.e. at the concentrations at which said polymer exhibited the best mucoadhesive properties (Junginger, op. cit., 1991).

In particular, the adhesion work, i.e. the force of adhesion (separation) by elongation of the mucin surfaces, was measured. The tests were carried out according to the methods described in literature (Saettone et al., Int.J.Pharm., 51, 203-212, 1989), in the absence of dipping solution.

The formulation under examination (75 µl) was stratified on the upper support provided with a centrally pierced ring nut limiting the surface (inside diameter of 1.20 cm). The measurement (platform fall rate 2.50 mm/min) was made after 1 min of contact between the surfaces.

The data obtained by recording the force (F) required for separating the two surfaces (formulation and mucous layer), as a function of the elongation (l) of same, were processed by a computer. The area under the curve obtained (AUC), representing the adhesion work (L) (F.l), was thus calculated.

Table 2 shows the values and the average values \pm S.E. (expressed as erg/cm²) of the AUCs of the compositions under investigation as well as the average values of a reference formulation (polyacrylic acid [Carbopol 940®], 2.5% neutralized gel) and of mucin (swine gastric mucin [Tokyo Kasei Kogyo, Japan], 25.0% dispersion).

Tabl 2 AUC values of bioadhesive matrices.

comp. n°	A	B	C	D	E	F	G	H	I	C940 ®	Mucin
1	457.08	381.11	608.13	398.91	497.01	803.46	742.69	474.00	524.36		
2	361.15	339.88	601.62	485.29	637.65	666.30	861.40	554.74	483.99		
3	375.47	438.41	539.98	499.18	760.06	579.92	923.26	619.85	402.82		
4	374.60	411.06	462.72	408.89	539.98	576.44	793.04	520.45	489.19		
5	441.45		460.11	405.85	553.00		993.58	428.86	380.68		
6							827.55	574.27			
average	401.95	392.61	534.51	439.62	597.54	656.53	856.92	528.69	456.21	304.23	118.20
S.E.	19.64	21.12	32.13	21.65	46.60	53.20	37.00	28.34	27.44	26.63	9.00

The experimental results prove that Polycarbophil has excellent bioadhesiveness and adhesion strength and that there is no significant difference between the bioadhesive properties of Polycarbophil at a concentration of 1% by wt. (A) and at a concentration of 0.2% by wt. (B).

- 5 The mucoadhesion strength of all tested formulations (C to I) is much higher than that of mucin and of C940[®], and even of Polycarbophil (A and B), which suggests that the association of biopolymers at different concentrations can improve the adhesion strength and therefore mucoadhesive properties.

Measurements of rheological properties

- 10 In order to check whether said compositions, besides exhibiting improved bioadhesive properties, also had significant rheological properties, viscosity measurements, flow curves and oscillatory measurements were carried out to evaluate the viscoelastic behaviour.

Viscosity measurements and flow curves

The samples (A,B,C,D,G,H, and I) were analyzed with a viscometer HAAKE[®] RS100, with flat-cone measurement system C35/4° at 23°C, and compared within the same range of applied stress (0-50 Pa). Flow curves (rheograms) were recorded (Figures 1a to 7a): the conical rotor was subjected to a shear rate and, at the same time, stress τ and viscosity η were recorded. Table 3 shows the viscosity values obtained at a constant shear rate $\dot{\gamma}$. A shear rate of 50 sec^{-1} was chosen for low viscosity samples and a shear rate of 0.5 sec^{-1} for high viscosity samples.

Table 3 Viscosity η of bioadhesive matrices

Comp. Ref.	A	B	C	D	E	F	G	H	I
$\eta / 50 \text{ s}^{-1}$ (Pa.s)		0.800		0.400				0.550	0.220
$\eta / 0.5 \text{ s}^{-1}$ (Pa.s)	100		100		—	—	73		

Viscosity η was measured in Pascal.sec (Pa.s).

Oscillatory measurements

The samples (A,B,C,D,G,H, and I) were analyzed with a viscometer HAAKE[®] RS100, with flat-cone measurement system C35/4° at 23°C, with oscillation frequency varying from 0.0464 to 4.64 Hz and an applied stress of 0.50 Pa for samples B, D, H and I and of 4.00 Pa for samples A, C and G.

The oscillatory measurements, made to distinguish the "viscous" from the "elastic" character of the formulations, gave the results shown in Fig. 1b to 7b.

Sample B (0.2% Polycarbophil) was found to be a "stiff gel", the elastic modulus (G')/viscous modulus (G'') ratio being high. The values of said elastic modulus (G') and viscous modulus (G'') are constant and parallel with varying rotor angular speed, which further indicates a "stiff gel"

- 27 -

structure. A probable creep limit is observed (Fig. 1b).

Sample A (1% Polycarbophil) shows an analogous behaviour, but the non-linear, i.e. slightly curvilinear, trend of the δ -Cor angle (displacement angle between vectors G' and G'') with varying rotor angular speed indicates a lower stability of the gel, while probable fracture effects appear in its structure (Fig. 2b).

That is the intrinsic behaviour of Polycarbophil; instead, when it is mixed with other polymers, the gel is destructured: the creep limit value decreases until disappearing when passing from B (Fig. 1b) to D (Fig. 3b). Among the investigated compositions containing 0.2% Polycarbophil, sample H exhibits the highest viscosity. Furthermore, its viscoelastic behaviour is particularly interesting, since the elastic modulus increases more markedly than the viscous modulus, which indicates that sample H tends to change from stiff gel to viscous polymer. Said behaviour seems to be due to the presence of hyaluronic acid and to result from the average molecular weight and from the molecular weight distribution of the polymers in solution (Fig. 4b).

Sample I, which is characterized by the presence of low molecular weight dermatan sulfate, has lower viscosity than sample H, associated with the lower average molecular weight of the polysaccharide. In any case, said sample exhibits an interesting behaviour, analogous to that of newtonian liquids, the trend of the stress τ /shear rate $\dot{\gamma}$ ratio being almost linear (Figs. 5a, b).

Sample C, compared with sample A, appears as a polymer solution rather than a stiff gel, which indicates that the physicochemical properties of the polysaccharide hyaluronic acid prevail over those of Polycarbophil (Fig. 6b).

- 28 -

Sample G is substantially a very viscous polymer solution. The curve representing the viscous modulus intersects the curve representing the elastic modulus at high angular speed values, which suggests the presence of a high average molecular weight polymer and a good molecular weight distribution (Fig. 7b).

It may be noted that the association of synthetic polymers, such as Polycarbophil and polyvinyl alcohol, with biopolymers, such as alginic acid, hyaluronic acid and dermatan sulfate, yields compositions with a marked bioadhesive behaviour and with the viscous character prevailing over the elastic one. This is an undoubted advantage, the "adhesiveness" being a property more closely related to the viscous modulus than to the elastic one and being the basis of the film-forming ability of said compositions.

In fact, if the "stiff gel" type rheological behaviour of Polycarbophil is modified by adding the aforesaid compositions with a viscous component, said compositions show not only improved adhesive properties but above all an improved film-forming ability. Thanks to their improved bioadhesiveness and viscosity, the compositions of the invention can provide stable films on the tissue to be treated, securing a better contact surface between the compositions and the same tissue and, consequently, a more adequate protection and/or moisturizing.

According to the aforesaid experimental results, the compositions of the invention have higher bioadhesive and, in particular, mucoadhesive properties than Polycarbophil, which is to date regarded as the molecule with the best bioadhesive properties, utilized in various formulations suitable for moisturizing mucous membranes and for releasing drugs at a controlled rate after oral or topical administration.

- 29 -

The bioadhesive compositions of the invention, formulated as hydrogels and/or viscous solutions with varying rheological consistency (from semisolid to apparently liquid) depending on the intended applications, are therefore meant to treat pathological conditions or even less severe alterations associated with the so-called paraphysiological situations in the following districts:

Cutaneous:

- a) due to their moisturizing properties, useful in dryness/dehydration conditions caused by environmental factors or deriving from particular pharmacological treatments (e.g. keratolytic) or secondary to other diseases, e.g. eczema and dermatitis, or in situations for which tissue moisturizing is very important, e.g. decubitus ulcers;
- b) due to their bioadhesive properties, in association with antimycotics, steroid and non-steroid anti-inflammatory agents or antibacterial agents for treating mycosis, burns and ulcers of different nature.

Ophthalmic:

- a) as moisturizers/humectants in the treatment of disorders such as keratitis sicca or neuroparalytica, or of diseases simply caused by atmospheric factors or by foreign bodies fitting over the cornea, such as contact lenses;
- b) as mucoadhesive matrix capable of increasing the contact time of specific drugs contained therein, necessary for the pathology under treatment.

The intraocular concentration of a drug is partly determined by the rate of its elimination from the conjunctival and episcleral circl . In fact, the typical vasodilatation of the ye involves a faster outflow of the active principle administered: it is, therefore, very important to

- 30 -

prolong the contact time between the drug and the corneal epithelium.

In particular, said drugs may be for example anti-inflammatory agents, anti-histamines for treating external eye diseases of allergic origin, antimycotics for treating keratites, specific antibiotics for treating
5 viral infections, or antiglaucomatous or vasoactive agents.

Buccal:

a) in the form of mouthwash or gel, due to their moisturizing characteristics for treating xerostomia, both caused by irradiating treatments and associated with Sjögren's syndrome, senility or
10 administration of drugs, such as tricyclic antidepressants;

b) in the form of a specific mouthwash, gel or paste, associated with oral cavity disinfectants for daily hygiene, for treating infections, or associated with antimycotics/antibiotics and anti-inflammatory agents for treating diseases such as for example candidiasis, muguet,
15 stomat mucositis, paradontopathy, dental plaque and dismicrobism.

Tracheobronchial:

a) in the form of vapourization, due to their moisturizing and humectant characteristics, for treating dryness;

b) associated with antibiotics/antibacterial agents and/or anti-
20 inflammatory agents for treating the inflammation of the upper respiratory tract.

Vaginal:

a) in the form of gynaecologic wash, due to their humectant characteristics, for treating vaginites of various nature, accompanied by
25 mucosal dryness;

b) as a matrix capable of releasing drugs at a controlled rate, in particular in association with specific antimycotics, antibacterial or

- 31 -

anti-inflammatory agents.

Gastroenteric and rectal:

a) due to their mucoadhesive and film-forming properties, for treating diarrhoea and consequent dehydration, and due to their ability to gel

5 when coming into contact with water;

b) as a drug-delivery system, associated with drugs that would be insufficiently or variably absorbed by other administration routes or requiring a hepatic by-pass.

We report hereinbelow for illustrative but not limitative purposes the
10 following examples of the pharmaceutical compositions according to the present invention, useful per se for the treatment of dryness conditions in the aforesaid districts.

EXAMPLE 10

Ophthalmic fluid gel (by wt. % composition)

	Polyvinyl alcohol	1.50
	Polycarbophil	0.20
15	Hyaluronic acid	0.15
	Thimerosal	0.01
	Sodium chloride	0.65
	Disodium hydrogen phosphate $\cdot 12H_2O$	0.30
	Sodium dihydrogen phosphate $\cdot 2H_2O$	0.03
20	Demineralized water	q.s. to 100

EXAMPLE 11

Eyewash (by wt. % composition)

	Polyvinyl alcohol	0.15
	Polycarbophil	0.20
	Hyaluronic acid	0.15

- 32 -

	Thimerosal	0.01
	Sodium chloride	0.65
	Disodium hydrogen phosphate.12H ₂ O	0.30
	Sodium dihydrogen phosphate.2H ₂ O	0.03
5	Demineralized water	q.s. to 100

EXAMPLE 12

Eyewash (by wt. % composition)

	Polycarbophil	0.20
	Dermatan sulfate	0.30
	Thimerosal	0.01
	Sodium chloride	0.65
10	Disodium hydrogen phosphate.12H ₂ O	0.30
	Sodium dihydrogen phosphate.2H ₂ O	0.03
	Demineralized water	q.s. to 100

EXAMPLE 13

Gynaecologic gel (by wt. % composition)

	Polyvinyl alcohol	1.50
	Triethanolamine	1.50
15	Polycarbophil	1.00
	Sodium alginate	1.00
	Methyl p-hydroxybenzoate	0.10
	2-Phenylethanol	0.10
	Ethyl p-hydroxybenzoate	0.10
20	Demineralized water	q.s. to 100

EXAMPLE 14

Dermatologic gel (by wt. % composition)

	Polyvinyl alcohol	1.50
--	-------------------	------

- 33 -

	Triethanolamine	1.50
	Polycarbophil	1.00
	Sodium alginate	2.00
	Methyl p-hydroxybenzoate	0.10
5	2-Phenylethanol	0.10
	Ethyl p-hydroxybenzoate	0.10
	Demineralized water	q.s. to 100

EXAMPLE 15

Dental gel (by wt. % composition)

	Polyvinyl alcohol	1.50
	Triethanolamine	1.50
10	Polycarbophil	1.00
	Sodium alginate	3.00
	Methyl p-hydroxybenzoate	0.10
	2-Phenylethanol	0.10
	Ethyl p-hydroxybenzoate	0.10
15	Demineralized water	q.s. to 100

The compositions of the present invention may also be used as vehicles of active principles useful for the treatment of cutis and mucous membranes diseases. We report hereinbelow for illustrative but not limitativ purposes the following examples.

EXAMPLE 16

Gynaecologic gel (by wt. % composition)

20	2-Ph nylph nol	0.30
	Methyl p-hydroxybenzoate	0.10
	Ethyl p-hydroxybenzoat	0.10
	*Eumulgin HRE 40 [®]	1.00

- 34 -

	Triethanolamine	0.20
	Polycarbophil	1.00
	Polyvinyl alcohol	1.50
	Hyaluronic acid	0.10
5	Vitamin A Palmitate 2.000 IU/g	0.20
	Hyaluronic acid salt (Ex. 7)	0.06
	Chondroitin 6-sulfate	0.20
	Demineralized water	q.s. to 100
	* Eumulgin HRE 40 [®] : polyoxyethylenated castor oil	

EXAMPLE 17

Dermatologic gel (by wt. % composition)

10	2-Phenylphenol	0.30
	Methyl p-hydroxybenzoate	0.10
	Ethyl p-hydroxybenzoate	0.10
	Eumulgin HRE 40 [®]	1.00
	Triethanolamine	0.275
15	Polycarbophil	1.00
	Polyvinyl alcohol	1.00
	Hyaluronic acid	0.15
	Vitamin A Palmitate 2.000 IU/g	0.20
	Hyaluronic acid salt (Ex. 6)	0.06
20	Dodecenedioic acid	0.05
	Demineralized water	q.s. to 100

EXAMPLE 18

Gynaecologic solution (by wt. % composition)

	2-Phenylphenol	0.30
	Methyl p-hydroxybenzoate	0.10

- 35 -

	Ethyl p-hydroxybenzoate	0.10
	Eumulgin HRE 40 [®]	1.00
	Hydroxyethylcellulose	0.50
	Lactic acid (80%)	2.00
5	Triethanolamine	2.30
	Polycarbophil	0.20
	Polyvinyl alcohol	0.30
	Hyaluronic acid	0.15
	Vitamin A Palmitate 2,000 IU/g	0.20
10	Hyaluronic acid salt (Ex. 3)	0.20
	Demineralized water	q.s. to 100

EXAMPLE 19**Dermatologic gel (by wt. % composition)**

	2-Phenylphenol	0.30
	Methyl p-hydroxybenzoate	0.10
	Ethyl p-hydroxybenzoate	0.10
15	Eumulgin HRE 40 [®]	1.00
	Polycarbophil	1.00
	Polyvinyl alcohol	1.50
	Dermatan sulfate	0.15
	Vitamin A Palmitate 2,000 IU/g	0.20
20	Quercetin	0.01
	Dermatan sulfate salt (Ex. 4)	0.06
	Triethanolamin	0.25
	Chondroitin 6-sulfate	0.20
	Demineralized water	q.s to 100

EXAMPLE 20

- 36 -

Gynaecologic gel (by wt. % composition)

	Glycerin	10.00
	Eumulgin HRE 40 [®]	2.00
	Polycarbophil	1.00
	Hyaluronic acid	0.30
5	Triethanolamine	0.25
	Vitamin A Palmitate 2,000 IU/g	0.20
	Methyl p-hydroxybenzoate	0.10
	Ethyl p-hydroxybenzoate	0.10
	2-Phenylethanol	0.15
10	Methyl Paraben	0.10
	Dodecenedioic acid, cetrimide salt	0.05
	N-(2-hydroxyethyl)-hexadecanamide	0.01
	Demineralized water	q.s. to 100

EXAMPLE 21

Eyewash (by wt. % composition)

	Polycarbophil	0.20
15	Dermatan sulfate salt (Ex. 5)	0.30
	Thimerosal	0.01
	Sodium chloride	0.65
	Disodium hydrogen phosphate.12H ₂ O	0.30
	Sodium hydrogen phosphate.2H ₂ O	0.03
20	Demineralized water	q.s. to 100

EXAMPLE 22

Dental gel (by wt. % composition)

	Polyvinyl alcohol	1.50
	Triethanolamine	1.50

- 37 -

	Polycarbophil	1.00
	Dermatan sulfate salt (Ex. 8)	3.00
	Methyl p-hydroxybenzoate	0.10
	2-Phenylethanol	0.10
5	Ethyl p-hydroxybenzoate	0.10
	Demineralized water	q.s. to 100

EXAMPLE 23

Dermatologic gel (by wt. % composition)

	Polyvinyl alcohol	1.50
	Triethanolamine	1.50
	Polycarbophil	1.00
10	Dermatan sulfate (Ex. 2)	2.00
	Methyl p-hydroxybenzoate	0.10
	2-Phenylethanol	0.10
	Ethyl p-hydroxybenzoate	0.10
	Demineralized water	q.s. to 100

EXAMPLE 24

Gynaecologic gel (by wt. % composition)

15	Polyvinyl alcohol	0.20
	Polycarbophil	1.00
	Hyaluronic acid	0.10
	N,N'-bis-(2-hydroxyethyl)-nonandiamide	0.20
	Glycerin	10.00
20	Propyl ne glycol	1.00
	Hydrogenat d castor oil (40)OE*	1.00
	Tocopheryl acetate	0.50
	Ph nylethyl alcohol	0.15

- 38 -

Methyl p-hydroxybenzoate	0.10
Quercitin	0.01
Sodium hydroxide (30% by wt. solution)	0.20
Demineralized water	q.s. to 100

- 5 * Hydrogenated castor oil (40)OE is polyoxyethylenated with 40 moles ethylene oxide/mole.

EXAMPLE 25

Dental gel (by wt. % composition)

Polyvinyl alcohol	1.50
Polycarbophil	1.00
Sodium alginate	3.00
10 N,N'-bis-(2-hydroxyethyl)-nonandiamide	0.20
Triethanolamine	1.50
Methyl p-hydroxybenzoate	0.10
2-Phenylethanol	0.10
Ethyl p-hydroxybenzoate	0.10
15 Demineralized water	q.s. to 100

EXAMPLE 26

Dental gel (by wt. % composition)

Polyvinyl alcohol	0.200
Polycarbophil	0.200
Hyaluronic acid	0.050
N,N'-bis-(2-hydroxyethyl)-nonandiamide	1.000
20 Trans-2-dodecendioic acid	0.005
Xylitol	7.500
Carboxymethylcellulose sodium salt	4.500
Hydrogenated castor oil (40)OE*	0.500

- 39 -

	2,4-Dichlorobenzyl alcohol	0.150
	Cytromint	0.150
	Colour CI 42090	0.025
	Colour CI 19140	0.015
5	Demineralized water	q.s. to 100
	* Hydrogenated castor oil (40)OE is polyoxyethylenated with 40 mol s ethylene oxide/mole.	

EXAMPLE 27**Dental mouthwash (by wt. % composition)**

	Polycarbophil	0.1000
	Hyaluronic acid	0.0500
10	PTC*	57.1429
	N,N'-bis-(2-hydroxyethyl)-nonandiamide	0.0100
	Trans-2-dodecendioic acid	0.0005
	Xylitol	7.5000
	Polysorbate 20	1.0000
15	2,4-Dichlorobenzyl alcohol	0.1500
	Cytromint	0.1000
	Colour CI 42090	0.1000
	Demineralized water	q.s. to 100

* PTC (Polyphenolic Tea Complex) indicates an aqueous extract containing 20 0.15-0.4% by weight of D(+)-catechin, obtained by treating 1 kg of green tea (leaves) in demineralized water (20-30 l), at a temperature of 60-80°C, for a period of 10-30 minutes.

EXAMPLE 28**Dental spray (by wt. % composition)**

	P lyvinyl alcohol	0.200
--	-------------------	-------

- 40 -

	Hyaluronic acid	0.050	
	N,N'-bis-(2-hydroxyethyl)-nonandiamide	1.000	
	Trans-2-dodecendioic acid	0.005	
	Xylitol	7.500	
5	Hydrogenated castor oil (40)OE*	0.500	
	Cytromint	0.180	2,4-Dichlorobenzyllic
	alcohol	0.150	Demineralized water
			q.s. t
	100		

* Hydrogenated castor oil (40)OE is polyoxyethylenated with 40 m les
10 ethylene oxide/mole.

- 41 -

CLAIMS

- 1 1. A highly bioadhesive and mucoadhesive aqueous composition, useful in
2 the rehydration of the skin and mucosal tissues and/or as vehicle of
3 active principles in percutaneous absorption, containing:
4 - at least a synthetic polymer selected from the group consisting of
5 polyethylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, Carbopol
6 and derivatives thereof; and
7 - at least a biopolymer selected from the group consisting of hyaluronic
8 acid, dermatan sulfate, chondroitin sulfate, alginic acid and salts
9 thereof.
- 1 2. The aqueous composition according to claim 1, characterized in that
2 said synthetic polymer is Polycarbophil, in a quantity ranging from 0.1
3 to 2% by wt.
- 1 3. The aqueous composition according to claim 1, characterized in that
2 said synthetic polymer is polyvinyl alcohol, in a quantity ranging from
3 0.1 to 4% by weight.
- 1 4. The aqueous composition according to claim 1, characterized in that
2 said biopolymer is hyaluronic acid or salts thereof, in a quantity
3 ranging from 0.05% to 5% by weight.
- 1 5. The aqueous composition according to claim 4, characterized in that
2 said hyaluronic acid has an average molecular weight ranging from 800,000
3 to 1,200,000 daltons.
- 1 6. The aqueous composition according to claim 1, characterized in that
2 said biopolymer is alginic acid or salts thereof, in a quantity ranging
3 from 0.5% to 5% by weight.
- 1 7. The aqueous composition according to claim 1, characterized in that
2 said biopolymer is dermatan sulfate or salts thereof, in a quantity

- 42 -

3 ranging from 0.05% to 5% by weight.

1 8. The aqueous composition according to claim 7, characterized in that
2 said dermatan sulfate has an average molecular weight of 5,000 to 8,000
3 daltons.

1 9. The aqueous composition according to claim 1, characterized in that
2 said hyaluronic acid salts are selected from the group consisting of zinc
3 salt, mixed salt with biotin and ethylenediamine, and mixed salt with
4 traumatic acid and ethylenediamine. 10. The aqueous composition according
5 to claim 1, characterized in that said dermatan sulfate salts are
6 selected from the group consisting of lithium, zinc and
7 tetrabutylammonium salts, mixed salt with biotin and ethylenediamine, and
8 mixed salt with traumatic acid and ethylenediamine.

1 11. The aqueous composition according to claim 1, characterized in that
2 said composition is a binary, ternary or quaternary association of said
3 synthetic polymers and said biopolymers.

1 12. The aqueous composition according to claim 1, characterized in that
2 said mucosal tissues are selected from the group consisting of cutaneous,
3 ophthalmic, buccal, tracheobronchial, vaginal, gastroenteric and rectal
4 tissues.

1 13. The aqueous composition according to claim 1, characterized in that
2 said active principle to be vehiculated in percutaneous absorption is
3 selected from the group consisting of antimycotics, steroid and non-
4 steroid anti-inflammatory agents, antibacterial agents, anti-histamin s,
5 antibiotics, antiglaucomatous agents, vasoactive agents and
6 disinfectants.

1 14. A process for the preparation of highly bi adh sive and mucoadh siv
2 aqueous compositions, useful in the r hydration of the skin and mucosal

- 43 -

3 tissues and/or as vehicles of active principles in percutaneous
4 absorption, containing at least a synthetic polymer selected from the
5 group consisting of polyethylene glycols, polyvinyl alcohols,
6 polyvinylpyrrolidone, Carbopol and derivatives thereof, and at least a
7 biopolymer selected from the group consisting of hyaluronic acid,
8 dermatan sulfate, chondroitin sulfate, alginic acid and salts thereof,
9 comprising the following steps:

- 10 a) complete homogenization of one of said synthetic polymers in water;
- 11 b) optionally, complete homogenization, in a separate pot, of another one
12 of said synthetic polymers in water;
- 13 c) optionally, combination of the masses obtained in steps (a) and (b),
14 under continuous stirring, until complete homogenization;
- 15 d) preparation of a homogeneous solution of one of said biopolymers in
16 water;
- 17 e) addition of the solution obtained in (d) to the mixture obtained in
18 (c), under continuous stirring, until complete homogenization;
- 19 f) optionally, preparation of a water solution of a thickening agent,
20 followed by the addition of said solution to the mass obtained in step
21 (e), under continuous stirring, until complete gelling of the mass.

1 15. The process according to claim 14, characterized in that, in step
2 (f), said thickening agent is triethanolamine.

1 16. Use of highly bioadhesive and mucoadhesive aqueous compositions in
2 the treatment of skin and mucosal tissues dryness and dehydration,
3 wherein said compositions contain:

- 4 - at least a synthetic polymer selected from the group consisting of
5 polyethylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, Carbopol
6 and derivatives thereof; and

- 44 -

7 - at least a biopolymer selected from the group consisting of hyaluronic
8 acid, dermatan sulfate, chondroitin sulfate, alginic acid and salts
9 thereof.

1 17. The use according to claim 16, characterized in that said mucosal
2 tissues are selected from the group consisting of cutaneous, ophthalmic,
3 buccal, tracheobronchial, vaginal, gastroenteric and rectal tissues.

1 18. Use of highly bioadhesive and mucoadhesive aqueous compositions as
2 vehicles of active principles in percutaneous absorption, wherein said
3 compositions contain:

4 - at least a synthetic polymer selected from the group consisting of
5 polyethylene glycols, polyvinyl alcohols, polyvinylpyrrolidone, Carbopol
6 and derivatives thereof; and

7 - at least a biopolymer selected from the group consisting of hyaluronic
8 acid, dermatan sulfate, chondroitin sulfate, alginic acid and salts
9 thereof.

1 19. The use according to claim 18, characterized in that said active
2 principles to be vehiculated in percutaneous absorption are selected from
3 the group consisting of antimycotics, steroid and non-steroid anti-
4 inflammatory agents, antibacterial agents, anti-histamines, antibiotics,
5 antiglaucomatous agents, vasoactive agents and disinfectants.

1 20. A dermatan sulfate salt selected from the group consisting of zinc
2 salt, tetrabutylammonium salt, mixed salt with biotin and
3 ethylenediamine, and mixed salt with traumatic acid and ethylenediamine.

1 21. The salt according to claim 20, characterized in that said dermatan
2 sulfate has an average molecular weight ranging from 5,000 to 8,000
3 daltons.

1 22. A hyaluronic acid salt selected from the group consisting of zinc


- 45 -

2 salt, mixed salt with biotin and ethylenediamine and mixed salt with
3 traumatic acid and ethylenediamine.

1 23. The salt according to claim 22, characterized in that said hyaluronic
2 acid has an average molecular weight ranging from 800,000 to 1,200,000
3 daltons.


1/14

Fig. 1a




2/14

Fig. 1b




3/14




4/14

Fig. 2b




5/14

Fig. 3a




6/14

Fig. 3b




7/14

Fig. 4a




8/14

Fig. 4b




9/14

Fig. 5a




10/14

Fig. 5b




11/14

Fig. 6a



12/14

Fig. 6b



13/14

Fig. 7a





Fig. 7b



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/02999

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K7/48 A61K9/00 A61K7/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 8841 Derwent Publications Ltd., London, GB; Class A61, AN 88-289758 'Moisture-retaining lubricating mucosa-protecting agent' & JP,A,63 212 355 (KATSUSHIMA) , 5 September 1988 see abstract ---	1-5, 14-16
X	US,A,5 110 605 (ACHARYA) 5 May 1992 see column 9, line 45 - line 60; claims ---	1,2,6,13
X	EP,A,0 280 807 (BIOMATRIX) 7 September 1988 see claims 1-13 ---	1,4,5

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

24 November 1995

Date of mailing of the international search report

10. 01. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Loiselet-Taisne, S

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/EP 95/02999

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 8 no. 236 (C-249) ,30 October 1984 & JP,A,59 116207 (POLA KASEI K.K.K.) 22 December 1982, see abstract ---	1
Y	EP,A,0 393 904 (MAXAM INC.) 24 October 1990 see table ---	1,13-19
Y	EP,A,0 516 026 (TAKEDA CHEMICAL IND.) 2 December 1992 see page 3, line 19 - line 30 ---	1,13-19
X	WO,A,90 10020 (CHEMICAL WORKS OF GEDEON RICHTER LTD.) 7 September 1990 see page 1, line 19 - page 2, line 3; claims 1,5,7 ---	22
A	EP,A,0 516 141 (RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY) 2 December 1992 see page 6, line 40 - line 42 see page 6, line 58 - page 7, line 10; examples -----	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/02999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US-A-5110605	05-05-92	AU-B-	8444291	17-03-92
		EP-A-	0497956	12-08-92
		JP-T-	5502894	20-05-93
		WO-A-	9203124	05-03-92

EP-A-280807	07-09-88	AU-B-	610512	23-05-91
		AU-B-	7637787	16-06-88
		JP-A-	63156838	29-06-88
		US-A-	5266563	30-11-93

EP-A-393904	24-10-90	AU-B-	633892	11-02-93
		AU-B-	5296890	18-10-90
		CA-A-	2014437	17-10-90
		CN-A-	1047802	19-12-90
		JP-A-	3002118	08-01-91
		OA-A-	9739	30-11-93

EP-A-516026	02-12-92	JP-A-	5230313	07-09-93
		US-A-	5346935	13-09-94

WO-A-9010020	07-09-90	AU-B-	623232	07-05-92
		AU-B-	5108890	26-09-90
		CA-A-	2027596	25-08-90
		CN-A, B	1045394	19-09-90
		CN-A-	1086422	11-05-94
		DE-D-	69005394	03-02-94
		DE-T-	69005394	28-07-94
		EP-A-	0413016	20-02-91
		ES-T-	2061016	01-12-94
		GR-B-	1000869	16-03-93
		IE-B-	62408	25-01-95
		IL-A-	93489	30-05-94
		JP-T-	3505231	14-11-91
		PL-B-	163417	31-03-94
		RU-C-	2021304	15-10-94

EP-A-516141	02-12-92	IT-B-	1250421	07-04-95
		JP-A-	7215843	15-08-95
